ArticleNature communications2026
Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy.
Abstract read
In one paragraph
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors.
Winnie Fernando *The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.
Jarama Clucas *The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK. jarama.clucas@icr.ac.uk.ORCID http://orcid.org/0009-0002-2041-5652
Alberto Rizzo *The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.
Ramsay Singer *The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.
Emily Goode *The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.
Crescens TiuThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.ORCID http://orcid.org/0000-0002-0515-6130
Scott LayzellThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.
Joshua KonecnikThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.
Rebecca WilsonThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.
Sidonie Wicky JohnThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.
Samuel JounyThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.
Naomi GuppyThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.ORCID http://orcid.org/0000-0003-1004-3605
Victoire BoulatCancer Bioinformatics, School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.
Jonathan MannionThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.ORCID http://orcid.org/0000-0001-6054-3451
Maria GoicoecheaThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.
Shaun TanThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.
Sam LawsonThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.
Chris StarlingThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.ORCID http://orcid.org/0009-0007-5100-6663
Gabrielle ElshteinThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.
Nivedita RavindranThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.
Anna B MontgomeryCentre for Inflammation Biology and Cancer Immunology, School of Immunology & Microbial Sciences, King's College London, London, UK.
Rosa Andres-EjarqueCentre for Inflammation Biology and Cancer Immunology, School of Immunology & Microbial Sciences, King's College London, London, UK.ORCID http://orcid.org/0000-0003-0012-1155
Mark AllenBiological Services Unit, The Institute of Cancer Research, London, UK.
Steven LumbardBiological Services Unit, The Institute of Cancer Research, London, UK.
Fredrik WallbergQuell Therapeutics Ltd, Translation & Innovation Hub, London, UK.
Kai BetteridgeThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.
Ross ScrimgeourThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.ORCID http://orcid.org/0000-0003-1412-9748
David RobertsonThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.
George WardAstex Pharmaceuticals, Cambridge, UK.ORCID http://orcid.org/0000-0001-9960-3896
Martin SimsAstex Pharmaceuticals, Cambridge, UK.ORCID http://orcid.org/0009-0001-8684-6095
Tomoko SmythAstex Pharmaceuticals, Cambridge, UK.
Andre L SamsonThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-0637-2716
James M MurphyThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0003-0195-3949
Daniela Kolarevic IvankovicThe Royal Marsden NHS Foundation Trust, London, UK.
Esther N ArwertThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.
Dinis P CaladoImmunity and Cancer Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0001-8239-7184
Anita GrigoriadisCancer Bioinformatics, School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.ORCID http://orcid.org/0000-0003-3434-201X
Matthew J SmalleyThe European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Cardiff, UK.ORCID http://orcid.org/0000-0001-9540-1146
Alan MelcherThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.ORCID http://orcid.org/0000-0002-2042-3380
Syed HaiderThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.ORCID http://orcid.org/0000-0001-6685-5480
Toby LawrenceCentre for Inflammation Biology and Cancer Immunology, School of Immunology & Microbial Sciences, King's College London, London, UK.ORCID http://orcid.org/0000-0003-0967-6122
Ioannis RoxanisThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.
Andrew N J TuttThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.ORCID http://orcid.org/0000-0001-8715-2901
Tencho TenevThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK. tencho.tenev@icr.ac.uk.
Pascal MeierThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Fulham Road, London, UK. pascal.meier@icr.ac.uk.ORCID http://orcid.org/0000-0003-2760-6523
Funding
Breast Cancer Now (BCN) CTR-QR14-007Cancer Research UK (CRUK) C26866/A24399RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/W017261/1Worldwide Cancer Research 23-0146
Abstract
Immunotherapy has transformed cancer treatment, including early triple-negative breast cancer (TNBC), yet most patients with advanced TNBC fail to respond to immune checkpoint blockade (ICB) plus chemotherapy. Durable control likely requires not only tumour cell killing but also immunogenic cell death (ICD) that activates antitumour immunity. Using a Brca1
Indexed as
Immunogenic Cell DeathImmunotherapyNecroptosisStromal CellsTriple Negative Breast NeoplasmsAnimalsCell Line, TumorFemaleHumansImmune Checkpoint InhibitorsMiceMice, KnockoutReceptor-Interacting Protein Serine-Threonine KinasesTumor MicroenvironmentImmune Checkpoint InhibitorsReceptor-Interacting Protein Serine-Threonine KinasesRipk1 protein, mouse
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.